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4 Institute for Inflammation Research (IIR), Rigshospitalet University Hospital, Copenhagen, DenmarkPatients undergoing long-termhighly active antiretroviral therapy treatment are probably at a higher risk
of various HIV-related complications. Hyperactivation of The mammalian target of rapamycin (mTOR)
has been found to contribute to dysregulated apoptosis and autophagywhich determine CD4+-T-cell loss,
impaired functionof innate immunityanddevelopmentofneurocognitivedisorders.DysregulatedmTOR
activation has also been shown to play a key part in the development of nephropathy and in the
pathogenesisofHIV-associatedmalignancies.These studies stronglysupportamultifunctionalkey role for
mTOR in the pathogenesis of HIV-related disorders and suggest that specific mTOR inhibitors could
represent a novel approach for the prevention and treatment of these pathologies.mTOR and its pharmacological inhibitors:
multifunctional agonists and antagonists regulating
immune functions, cancer, aging, viral infection and
autism spectrum disorders
The mammalian target of rapamycin (mTOR), also known as
mechanistic target of rapamycin or FK506-binding protein 12-
rapamycin-associated protein 1 (FRAP1), is a 289 kDa protein
originally discovered and cloned from Saccharomyces cerevisiae that
shares sequence homologies with the phosphoinositide 3-kinase
(PI3-kinase) family and represents a serine/threonine protein
kinase that is present in all eukaryotic organisms [1].
mTOR plays a key part as an intracellular nutrient sensor that
controls protein synthesis, cell growth and metabolism [2]; it is
activated by different stimuli such as amino acids, growth factors
and oxygen. mTOR represents the catalytic subunit of two distinct
complexes, called mTORC1 and mTORC2 [2]. mTORC1 controls
cell growth by maintaining a balance between anabolic processes,
such as macromolecular synthesis and nutrient storage, and cata-
bolic processes, such as autophagy and the utilization of energy
stores [3,4]. mTORC2 regulates cell survival and cytoskeletal orga-Corresponding author:. Nicoletti, F. (ferdinic@unict.it)
1359-6446/06/$ - see front matter  2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.drudis.2011.05.008nization through the regulation of Akt and protein kinase C alpha
(PKCa), respectively [5].
Rapamycin (Rapamune1; sirolimus) is a macrolide first isolated
from the soil bacterium Streptomyces hygroscopicus [6]. It represents
the first-in-class of specific mTOR inhibitors. This class also
includes derivatives, termed rapalogs, which include temsiroli-
mus, everolimus and ridaforolimus. Some of these drugs have
been approved for the prevention of graft rejection and the treat-
ment of cancers. However, in agreement with the pleiotropic role
of mTOR in cell biology, several experimental studies indicate
beneficial effects of mTOR inhibitors in other conditions that
range from Parkinson’s disease to aging, viral infection and autism
[7–9].
When rapamycin binds to its intracellular receptor FK-binding
protein 12 (FKBP12) a complex is formed (rapamycin–FKBP12),
and this inhibits the ability of mTOR to phosphorylate the p70
ribosomal protein S6 kinase 1 (p70S6K) [10]. In doing so, rapa-
mycin interferes with the PI3K/Akt/mTOR axis which plays a key
part in several cellular functions, including differentiation, via-
bility and growth [2,11].When the PI3K pathway is activated (e.g.
by stress or growth factors), the consequent phosphorylation of
Akt activates TSC2, a large protein that, together with TSC1www.drugdiscoverytoday.com 715
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TSC2 acts as aGTPase-activating protein (GAP) for Ras homologue
enriched in brain (RHEB). GDP-bound RHEB cannot activate
mTORC1, thus turning off the mTORC1 signalling pathway.
Akt-mediated TSC2 phosphorylation is thought to inhibit the
GAP activity for RHEB, thus promoting mTORC1 activation. By
inhibitingmTOR, rapamycin blocks the above-mentioned signal-
ling cascade downstream; thusmodulating key events controlling
cellular growth [2]. A diagram depicting the PI3K/PTEN/Akt/
mTOR pathway where rapamycin, rapalogs, PI3K/mTOR and
mTOR inhibitors exert their effects on protein translation is
presented in Fig. 1.
Rapamycin also possesses in vitro and in vivo anti-HIV proper-
ties that qualify it as a potential new anti-HIV drug [12]. Indeed,
rapamycin represses HIV-1 replication in vitro through different
mechanisms including, but not limited to, downregulation of
C–C chemokine receptor type 5 (CCR5) (reviewed in Ref. [12]).
In addition, rapamycin synergistically enhances the anti-HIV
activity of entry inhibitors such as vicriviroc, aplaviroc and
enfuvirtide in vitro [12]. Rapamycin also inhibits HIV-1 infection
in human peripheral blood leukocyte reconstituted SCID mice
[13], and a recent prospective trial of liver-transplanted HIV
patients indicated significantly better control of HIV and hepa-
titis C virus replication in those receiving rapamycin mono-
therapy [14].
HIV and its treatment: advantages and some limits
of HAART
HIV is a genetically related member of the Lentivirus genus of the
Retroviridae family that shows a particular tropism for CD4+ T cells
[15]. However, the CD4 antigen alone is not sufficient for virus
entry, because a co-receptor is necessary to gain access into the
cells. These molecules belong to the family of seven-transmem-
brane domain G-protein-coupled receptors. Typically, CXCR4 is
used by strains with tropism for T cells and CCR5 by strains with
tropism for macrophages [16].
The course of HIV infection is characterized by a phase of acute
viremia associated with a rapid decrease in circulating CD4+ T cells
[17]. It has been shown that, despite a massive immune response,
the host fails to eliminate the virus which remains latent in the
body [18]. This condition allows the virus to establish a chronic
phase with progressive immunodeficiency that is determined
primarily by high cell turnover, immune activation and apoptosis
of CD4+ T cells [19].
Highly active antiretroviral treatment (HAART) consists of a
combination of different drugs that inhibit HIV replication [20].
Although HAART accounts for the significant decrease in AIDS-
related morbidity and mortality seen in recent years [21], an
increased rate of AIDS-related complications such as neurocog-
nitive disorders, nephropathy and malignancies are being
observed in patients with poor initial CD4+ recovery and in
patients with a CD4+ count higher than 200 cells per mm3
[22,23]. This could be caused by prolonged viral persistence,
chronic immune activation, incomplete immune reconstitution
and/or accelerated immune senescence. Thus, although HAART
has significantly increased the life expectancy ofHIV-seropositive
patients, several issues remain andnew and/or adjuvant therapies
are therefore strongly justified.716 www.drugdiscoverytoday.comCan mTOR dysregulation link HIV-1 infection to CD4+-T-
cell loss, impaired function of innate immunity,
dementia, nephropathy and malignancies?
mTOR and CD4+-T-cell loss
mTOR activation seems to play a pathogenetic part in the dysre-
gulated apoptosis of CD4+ T cells in HIV-1 patients through gp120-
mediated activation of theCD4/CXCR4 (or CCR5)/mTOR/p53 axis
[24]. In fact, mTOR can phosphorylate p53 on serine 15 involved
in Env-induced syncytial apoptosis [25]. The complex of the Env
glycoprotein expressed on the membrane of HIV-1-infected cells
can also induce apoptosis of uninfected cells expressing CD4 and
CXCR4 or CCR5 through interaction between Env-expressing
infected cells and uninfected cells [24,25].
It has been proposed that autophagy also plays a pathogenetic
part in the death of uninfected CD4+ T cells [26]. Because mTOR
inhibits the cellular mechanism of autophagy, this makes the net
contribution of mTOR to the mechanism of CD4+-T-cell depletion
more complex to decipher. However, a study questioned the
contribution of autophagy to CD4+-T-cell death [27] because
the authors reported reduction of the autophagy proteins
Beclin-1 and LC3-II following infection of human peripheral blood
CD4+ T cells or U937 cells with HIV-1. Beclin-1 mRNA expression
and autophagosomes were also reduced in HIV-1-infected cells
[27,28]. The in vivo evidence indicating that the blockade ofmTOR
with rapamycin neither prevents CD4+-T-cell decline in HIV-1-
infected SCID mice [13] nor fails to influence their numbers in
HIV-infected individuals receiving liver transplantation [14] seems
to suggest that promotion of autophagy via mTOR blockade does
not influence HIV-1-induced CD4+-T-cell death in vivo.
mTOR and impaired function of innate immunity during
HIV infection
Defective immunological function of cells of the macrophage
lineage is known to contribute to the pathogenesis of HIV-1
infection. Thus, stopping phagocytosis of opportunistic pathogens
such as Mycobacterium avium complex, Pneumocystis carinii, Tox-
oplasma gondii or Candida albicans by peripheral bloodmonocytes,
tissue macrophages and monocyte-derived macrophages follow-
ing in vivo and in vitro HIV-1 infection has been documented [29].
Late-stage development of opportunistic infections has therefore
been attributed to defectivemonocyte/macrophage signalling and
function in HIV-infected individuals [30].
mTOR activation inhibits the destruction of pathogenic micro-
organisms by macrophages by inhibiting autophagy; rapamycin
restores this macrophage inhibition. Cells infected with HIV-1
blocked rapamycin-induced autophagy and CD40-induced autop-
hagocytosis of T. gondii in bystander macrophage/monocytic cells.
These studies show that a pathogenic microorganism can impair
autophagy in non-infected cells by activating counter-regulatory
pathways, and that activation of mTOR is involved in this process.
In agreement with these findings it has also been demonstrated in
dendritic cells (DCs) that rapamycin-mediated autophagy induc-
tion exerts a better anti-BCG vaccine response [31]. This raises the
possibility of therapeutic manipulation of cell signalling to restore
autophagy in HIV-1 infection [30].
A recent study also shows that HIV-1 can impair innate immune
function bymTOR-mediated impaired autophagy of DCs [32]. The
limited immune response seen in the early events of HIV-1 trans-
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FIGURE 1
Overview of the PI3K/PTEN/mTOR pathway depicting the sites of action of various inhibitors that result in the regulation of protein translation. The PI3K/PTEN/Akt/
mTOR pathway can affect protein translation by regulating the mTORC1 and mTORC2 complexes. Growth factor (GF) stimulation results in growth factor receptor
(GFR) activation which can activate the Ras/PI3K/PTEN/Akt/mTOR pathway. Akt can phosphorylate and inhibit TSC2 and PRAS-40, resulting in mTORC1 activation.
Rapamycin and rapalogs target mTORC1 and block its activity, also resulting in inhibition of downstream p70S6K. Also shown in this diagram are the sites of
interaction with novel PI3K/mTOR dual inhibitors andmTOR inhibitors. These latter two classes of inhibitors directly inhibit the kinase activity of mTOR and/or PI3K,
whereas rapamycin and rapalogs block mTOR activity. The mTOR pathway profoundly affects mRNA translation. Many mRNAs important in immunology, cancer
and cell growth contain 50 untranslated sequences that are difficult to translate and are referred to as ‘weak’mRNAs. For efficient translation of these ‘weak’mRNAs
to occur, p70S6K and eIF4E must be active. Hence, rapamycin, rapalogs, PI3K/mTOR dual inhibitors and mTOR inhibitors target the translation of these crucial
survival mRNAs.
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noamphisomes in DCs that rely on mTOR-dependent pathways
[32]. HIV-1-induced inhibition of autophagy in DCs increases cell-
associated HIV-1 and transfer of HIV-1 infection to CD4+ T cells.
HIV-1- and mTOR-mediated downregulation of autophagy in DCs
impaired innate and adaptive immune responses. Immunoamphi-
somes in DCs engulf incoming opportunistic infections and
amplify pathogen degradation as well as Toll-like receptor
responses and antigen presentation [32]. The findings that HIV-
1 downregulates autophagy and impedes immune functions of
DCs in an mTOR-dependent manner could have therapeutic and
prophylactic implications for the use of specific mTOR inhibitors.
mTOR and HIV-associated neurocognitive disorders
With the introduction of HAART, AIDS dementia complex – or
HIV-associated dementia as it was termed later – largely disap-
peared from clinical practice. However, during the past few years
long-term infected and treated patients, including those withwell-
controlled infection, started to complain about milder memory
problems such as slowness and difficulties in concentration, plan-
ning and multitasking. Neuropsychological studies have con-
firmed that cognitive impairment occurs in 15–50% of patients,
being one of the most feared complications of HIV-1-infection.
Neurocognitive impairment can also affect adherence to treat-
ment and, ultimately, result in increased morbidity [33,34].
HIV-related neuropathology consists of microglial infiltration
throughout white and grey matter, reactive astrogliosis in the
cortex and in the central grey structures, and loss of neurons in
the hippocampus and in the basal ganglia [35]. HIV enters the CNS
through infected macrophages and resides in the microglia. The
number of infected glial cells in HIV patients is highly variable but
generally too low to explain the underlying process of encephalitis
[33,34]. Thus, it is believed that immunoinflammatory and/or
degenerative responses of the microglial cells to infection rather
than virus-mediated cell death can explain AIDS-related neuro-
pathogenesis [33,34].
Alizarei and co-workers have recently studied the role of autop-
hagy in microglia-induced neurotoxicity in primary rodent neu-
rons, as well as in primate and humans models [36,37]. They found
that products of microglia infected with simian immunodeficiency
virus (SIV) inhibited neuronal autophagy, resulting in decreased
neuronal survival. Thiswasassociatedwithadecrease inautophagy-
inducingproteins, a decrease inneuronal autophagyvesicles andan
increase in sequestosome-1/p62. Signs of autophagy dysregulation
associatedwithdementia and encephalitiswere also found inbrains
from HIV-infected individuals and SIV-infected monkeys. Assess-
ment of multiple biochemical markers of autophagic activity con-
firmed the inhibition of autophagy in neurons.
The contribution of dysregulated mTOR activity to this process
was confirmed by the induction of autophagy in neurons after
rapamycin treatment, and such treatment conferred significant
protection to neurons [36,37]. This complements a previous study
by Narducci and co-workers that showed that upregulation of
mTOR and PUMA a p53 inducible BH3-only protein, also occurs
in neurons of patients suffering from HIV-associated encephalitis
[38]. Taken together, these results prove that defects in autophagy
are involved in neurodegenerative processes that arise from glial,
as opposed to neuronal, sources, and that maintenance of autop-718 www.drugdiscoverytoday.comhagy could have a role in neuroprotection during HIV infection.
The decreased neuronal autophagy might sensitize cells to proa-
poptotic and other damaging mechanisms, leading to neuronal
dysfunction and death. Hence, new therapeutic approaches aimed
at boosting neuronal autophagy including mTOR blockade with
rapamycin are conceivable to prevent the development of HIV-
associated neurocognitive disorders and to treat those suffering
from these complications.
mTOR and HIV-associated nephropathy
HIV-associated nephropathy (HIVAN) is an important clinical
manifestation of HIV infection that develops in 33% of HIV-1
cases [39]. Clinically evident chronic kidney disease and subclini-
cal renal pathology can occur in patients with long-lasting HIV
infection. The pathogenesis of HIVAN involves the direct infection
of the renal epithelium following HIV infection [40].
The introduction of combination HAART has been followed by
a decline in the incidence of HIVAN [41] and with delayed pro-
gression of end-stage renal disease.
The fact that mTOR could be involved in the pathogenesis of
HIVAN is suggested by a recent study carried out in Tg26 trans-
genic mice that harbour the proviral transgene pNL4-3:d1443,
which encodes all of the HIV-1 genes with the exception of
GAG and POL and serves as a preclinical model of HIVAN [42].
These animals develop proteinuria at24 days of age and progress
into nephritic syndrome and renal failure. Parietal and visceral
epithelial cells had increased levels of mTOR phosphorylation
when compared with the FVB/N control mouse [42], and treat-
ment with rapamycin reduced the renal lesions, proteinuria and
uremia. Rapamycin also decreased tubular dilation, probably
caused by inhibition of protein synthesis and cell cycle progression
in tubular cells [42]. These findings concur with a role for mTOR in
the proliferative phenotype and the development of HIVAN, and
provide in vivo proof-of-concept for the beneficial effects of mTOR
inhibitors in this setting
mTOR and HIV-associated malignancies
The occurrence of HIV-associated malignancies represents a major
complication for immunocompromised HIV-infected individuals
[43]. Indeed, it has been shown that there is an association
between HIV and cancer, particularly anal cancer, Kaposi sarcoma
(KS), non-Hodgkin’s lymphoma (NHL), primary effusion lym-
phoma (PEL), primary brain lymphoma and Burkitt’s lymphoma
(BL) [44]. Several factors have been identified as culprits of malig-
nancies in the HIV patients, including impaired immunocompe-
tence, dysregulated immune responses, genomic instability,
chronic B-cell stimulation and opportunistic infections with onco-
genic viruses [45]. The severity of immune suppression is predic-
tive of mortality from AIDS- and non-AIDS-associated
malignancies and it has been proposed that HAART is effective
in preventing their occurrence only in the cases where CD4+ cell
counts are restored to at least 500 cells per mm3 [45]. Indeed,
circulating CD4+ cell count is the most predictive factor for all
malignancies apart from anal cancer [46], which is better predicted
by the duration of immunodeficiency.
Because the first reports between the association ofHIV infection
and neoplasia were published, there has been a dramatic change in
the incidence and epidemiology of AIDS-related malignancies. KS,
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Control andPreventionasAIDS-definingmalignancies.However, as
the development and use of HAART continues, especially protease
inhibitors, there has been a steady increase in non-AIDS-defining
malignancies, such as Hodgkin’s lymphoma (HL), lung cancer,
hepatocellular cancer and anal cancer – and a decline in AIDS-
defining neoplasias. These emerging malignancies present a new
challenge in the care of patients with HIV infection, and require
optimal treatment protocols that take into consideration the inter-
action between HAART and systemic chemotherapy [47].
Anal cancer
The incidence of anal cancer is progressively increasing among
HIV-infected patients undergoing HAART [48]. The treatment of
anal cancer relies upon traditional chemo- and radio-therapeutic
approaches, which are associated with highmorbidity and limited
effectiveness in patients with high-grade disease. The role of
mTOR in this setting has recently been investigated by Stelzer
and colleagues [49] in preclinical models of murine and human
anal cancer. The first model was based on the use of the HPV16
transgenicmouse, in which expression of the E6 and E7 oncogenes
in the epithelium of the anus, alongwith the topical application of
the carcinogen DMBA, causes the formation of a progressive
neoplastic disease that leads to anal carcinoma. The second model
comprises HPV16-positive human anal cancer xenografts passaged
subcutaneously in immunodeficient SCID and nude mice. In both
models, anal cancers were associated with activation of the mTOR
pathway, and rapamycin significantly reduced their growth rates.
In the transgenic mouse model the prophylactic administration of
rapamycin also significantly reduced the incidence of the overall
onset of tumours, which include benign and malignant lesions.
Kaposi’s sarcoma
In the HAART era, KS remains the secondmost frequent tumour in
HIV-infected patients worldwide, and themost common cancer in
Sub-Saharan Africa. Patients with KS in Sub-Saharan Africa have
high tumour burdens and rapid disease progression with a life
expectancy <6 months. KS has a variable clinical course ranging
from extremely indolent forms, requiring no or minimal therapy,
to rapidly progressive disease. Several different therapeutic options
are available but the optimal therapy is still unclear. HAART,
including protease inhibitors, could represent the first treatment
step for slowing progressive disease; chemotherapy plus HAART is
indicated for visceral and/or rapidly progressive disease, whereas
maintenance HAART after systemic chemotherapy could be an
effective anti-KS measure. The angiogenic nature of KS makes it
particularly suitable for therapies based on targeted agents such as
metalloproteinase inhibitors, angiogenesis inhibitors and tyrosine
kinase inhibitors [50].
The identification of the KS-associated herpes virus (KSHV or
HHV8) as the viral etiologic agent of KS has prompted renewed
interest in the molecular pathogenesis of this disease. Evidence
now points to a single KSHV gene, vGPCR, as being essential for KS
development, and recent work has identified the Akt/TSC/mTOR
signalling cascade as a crucial pathway in vGPCR sarcomagenesis.
Indeed, pharmacological inhibition of mTOR with rapamycin has
shown promising results in preventing vGPCR-induced tumour-
igenesis in an animal model (see Ref. [51] for a review). Theseobservations are further validated by coincidental reports demon-
strating the efficacy of rapamycin as an immunosuppressive and
antitumoural solution for post-transplant KS patients [52].
Although confirmation of these observations in controlled
clinical trials is needed, these data seem to point to an important
role for mTOR in the pathogenesis of KS and suggest that mTOR
inhibitors could represent a novel therapeutic option for the
treatment of this condition in HIV-infected individuals.
Lymphomas
Lymphomas comprise a large proportion of the malignancies that
affect the HIV-infected population in developed countries. In
particular, NHL represents the most common tumour in HIV-
infected patients and represents an AIDS-defining illness since
the establishment of HAART therapy [53].
The incidence of AIDS-related lymphoma (ARL) has been found
to be 200-fold higher than the incidence of lymphoma in unin-
fected individuals. ARLs are often associated to herpes virus-g, EBV
or HHV-8 [43]. It is believed that B-cell proliferation stimulated by
chronic antigenaemia can result in polyclonal and eventually
monoclonal lymphoproliferation [43]. Standard treatment for
HIV lymphomas includes immune reconstitution using HAART,
anti-CD20 monoclonal antibodies, radioimmunotherapy, stem
cell transplantation, cytokine therapy and vaccination. Because
the prognosis for HIV-associated NHL nears that of the general
population, these approaches are of increasing importance. How-
ever, treatment of HIV-associated lymphomas could be hindered
by the difficulty of delivering full-dose chemotherapy to patients
with compromised bonemarrowor those suffering from infectious
diseases. This might explain the lower responses and survival rates
in HIV-associated lymphomas as compared with those of HIV-
seronegative patients [54]. Novel therapeutic options for HIV-
associated lymphomas are therefore warranted.
El-Salem and colleagues [55] showed that the mTOR signalling
pathway is activated in all patients with ARLs, regardless of their
histological classification. In particular, they found that mTOR is
activated in germinal centre cells and in the interfollicular areas,
but not in the resting lymphocytes of the benign HIV-associated
lymphadenopathy. Along with the reported occurrence of mTOR
activation in non-HIV-associated lymphomas [56], these data
suggest that the use of mTOR inhibitors could have potential
therapeutic effects in HIV-associated and non-HIV-associated lym-
phomas. Although large studies to support the potential use of
mTOR inhibitors against HIV-associated lymphomas are not avail-
able, it is interesting to observe that post-transplant lymphopro-
liferative disorder (PTLD)-type cell lines are highly sensitive to
mTOR inhibition [57] and that substitution of immunosuppres-
sive therapies based on inhibitors of calcineurin with mTOR-
inhibitor-based therapies in organ-transplanted patients reduced
the occurrence of PTLD lesions [58].
PEL constitutes a subset of NHL and PEL incidence is highly
increased in HIV-infected patients. KS-associated herpes virus is
the causative agent of PEL. PEL has a poor prognosis with reported
median survival times of <6 months. PEL displays activated PI3K,
Akt and mTOR. Although single modulation of the mTOR path-
way inhibited PEL proliferation, it has been reported that dual
inhibition of PI3K andmTOR was significantly more efficacious in
culture and in a PEL xenograft tumour model [59]. These datawww.drugdiscoverytoday.com 719
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FIGURE 2
mTOR involvement in HIV-associated diseases. During HIV infection, defects in autophagy are involved in neurodegenerative processes that arise from glia. The
decreased neuronal autophagy can sensitize cells to proapoptotic and other damaging mechanisms, leading to neuronal dysfunction and death. mTOR
hyperactivation also seems to play a pathogenetic part in the dysregulated apoptosis of CD4+ T cells in HIV-1 patients through gp120-mediated activation of the
mTOR-p53 axis. Finally, increased phosphorylation levels of S6K1 and 4EBP1 that occur upon HIV infection could also alter renal homeostasis causing nephropathy,
and might be involved in cell growth and metabolism, which could lead to tumour development.
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of targeting the PI3K/mTOR axis with specific inhibitors for the
treatment of PEL in HIV-infected patients [59].
Mantle-cell lymphoma (MCL), a well-defined subtype of B-cell
non-Hodgkin’s lymphoma (B-NHL), accounts for 6% of all lym-
phoid neoplasms, and has a median survival of 3–4 years. Recent
studies show that most cases of MCL exhibit constitutive activa-
tion of PI3K/Akt/mTOR pathways, which promotes tumour pro-
liferation and survival. In agreement with this, relapsed or
refractory MCL patients in a Phase III clinical study have shown
a better response to treatment with the specific mTOR inhibitor
temsirolimus than the investigator’s choice therapy [60]. These
data warrant the use of mTOR inhibitors in HIV-associated MCL.
Concluding remarks
The data discussed indicate that hyperactivation of mTOR occurs
in different pathologies associated with HIV infection such as
nephropathy and AIDS-associated and non-AIDS-associated
malignancies. Hyperactivation of mTOR could also be responsible
for defective autophagy that can contribute to the pathogenesis of720 www.drugdiscoverytoday.comneurocognitive disorders during HIV infection (Fig. 2). Preclinical
evidence indicates that selective inhibitors of mTOR such as
rapamycin could represent a novel therapeutic approach for the
treatment of these pathologies. HIV-infected patients could addi-
tionally benefit from the use of rapamycin because of its non-
mTOR-mediated capacity to inhibit HIV replication [12].
Although, the use of an immunosuppressive drug such as rapa-
mycin might raise the concern of increasing the immunodefi-
ciency of HIV-infected patients, the fact that mTOR inhibitors
have already proven effective in preventing some lymphoproli-
ferative disorders in transplant patients, who are also immuno-
compromised [52,58], suggests that the direct effects of mTOR
inhibitors could outweigh their immunosuppressive benefits in
the clinical setting.
These data indicate that the potential use of mTOR inhibitors,
either alone or in association with HAART, warrants that they are
studied in Phase II proof-of-concept trials designed to determine
whether the inhibition of mTOR ameliorates the natural course of
the infection and reduces the risk of developing HIV-associated
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